Edition:
India

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,510.00GBp
30 Oct 2020
Change (% chg)

-29.00 (-1.14%)
Prev Close
2,539.00
Open
2,525.00
Day's High
2,545.00
Day's Low
2,493.00
Volume
392,690
Avg. Vol
680,186
52-wk High
2,737.00
52-wk Low
1,596.00

Latest Key Developments (Source: Significant Developments)

Hikma Pharma Says HY Core Operating Profit Up 15%
Friday, 7 Aug 2020 

Aug 7 (Reuters) - Hikma Pharmaceuticals PLC ::H1 OPERATING PROFIT 297 MILLION USD VERSUS 238 MILLION USD YEAR AGO.H1 REVENUE ROSE 9 PERCENT TO 1.132 BILLION USD.HIKMA - HY CORE GROUP REVENUE UP 9%, REFLECTING GROWTH IN ALL THREE BUSINESSES.HIKMA- HY CORE OPERATING PROFIT UP 15%, DRIVEN BY A STRONG PERFORMANCE IN INJECTABLES.HIKMA - REPAID $500 MILLION EUROBOND DUE IN APRIL AND ISSUED NEW $500 MILLION EUROBOND IN JULY.HIKMA - ANNOUNCED INTERIM DIVIDEND OF 16 CENTS PER SHARE, UP FROM 14 CENTS PER SHARE IN H1 2019.HIKMA - INJECTABLES REVENUE NOW EXPECTED TO BE BETWEEN $950 MILLION AND $980 MILLION, WITH CORE OPERATING MARGIN IN RANGE OF 38% TO 40% FOR 2020.HIKMA - GENERICS REVENUE NOW EXPECTED TO BE IN RANGE OF $720 MILLION TO $760 MILLION FOR 2020.HIKMA - BRANDED REVENUE EXPECTED TO GROW IN MID-SINGLE DIGITS IN CONSTANT CURRENCY FOR 2020.HIKMA - CONTINUE TO WORK CLOSELY WITH OUR SUPPLIER NETWORKS AND HAVE NOT ENCOUNTERED ANY SUPPLY CHAIN ISSUES TO DATE..HIKMA - PROACTIVELY MANAGING OUR INVENTORY AND STOCK LEVELS, TRANSPORTATION OPTIONS AND AVAILABILITY OF RAW MATERIALS AND COMPONENT PARTS.HIKMA- ANNOUNCED INTERIM DIVIDEND OF 16 CENTS PER SHARE, UP FROM 14 CENTS PER SHARE IN H1 2019.  Full Article

Darhold Ltd Discloses 26.04% Stake In Hikma As At June 23 - Filing
Tuesday, 23 Jun 2020 

June 23 (Reuters) - Hikma Pharmaceuticals PLC ::DARHOLD LTD DISCLOSES 26.04% STAKE IN HIKMA AS AT JUNE 23 VERSUS PRIOR STAKE OF 24.66% - FILING.  Full Article

Boehringer Ingelheim Intends To Sell Up To About 28 Mln Shares In Hikma
Monday, 22 Jun 2020 

June 22 (Reuters) - Hikma Pharmaceuticals PLC ::J.P. MORGAN SEC PLC HIKMA PHARMACEUTICAL - PROPOSED PLACING IN HIKMA PHARMACEUTICALS PLC.J.P. MORGAN SECURITIES PLC- BOEHRINGER INGELHEIM INVEST GMBH SAYS INTENTION TO SELL UP TO ABOUT 28 MILLION SHARES IN HIKMA.J.P. MORGAN SECURITIES PLC - PLACING SHARES WILL BE OFFERED BY WAY OF AN ACCELERATED BOOKBUILD OFFERING.  Full Article

Sun Pharma, Hikma Sign Exclusive Licensing Deal For Ilumya For MENA Region
Monday, 15 Jun 2020 

June 15 (Reuters) - Sun Pharmaceutical Industries Ltd ::SUN PHARMA AND HIKMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR ILUMYA FOR MIDDLE EAST & NORTH AFRICA REGIONS.HIKMA WILL BE RESPONSIBLE FOR REGISTRATION AND COMMERCIALIZATION OF PRODUCT IN ALL MENA MARKETS.SUN PHARMA WILL BE RESPONSIBLE FOR PRODUCT SUPPLY.IS ELIGIBLE FOR UPFRONT AND MILESTONE PAYMENTS FROM HIKMA.TERM OF THIS AGREEMENT IS 15 YEARS FROM FIRST SALE, WITH TWO YEARS' AUTOMATIC RENEWAL PERIODS.  Full Article

Hikma Pharmaceutical U.S. Subsidiary Receives FDA Approval For Generic Vascepa
Friday, 22 May 2020 

May 22 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA RECEIVES FDA APPROVAL FOR GENERIC VASCEPA®.SUBSIDIARY HIKMA PHARMACEUTICALS USA RECEIVED APPROVAL FROM U.S. FDA FOR ITS ICOSAPENT ETHYL CAPSULES, 1 GM, GENERIC EQUIVALENT TO VASCEPA.  Full Article

Hikma Launches Propofol Injectable Emulsion, USP, In Response To COVID-19 Shortage
Tuesday, 12 May 2020 

May 12 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA RESPONDS TO COVID-19 SHORTAGE WITH LAUNCH OF PROPOFOL INJECTABLE EMULSION, USP.HIKMA - LAUNCH OF PROPOFOL INJECTABLE EMULSION, USP, 20 ML, 50 ML AND 100 ML VIALS, IN UNITED STATES.HIKMA - PROPOFOL INJECTABLE EMULSION IS CURRENTLY ON FDA'S DRUG SHORTAGE LIST, FOLLOWING A SURGE IN DEMAND DURING COVID-19 PANDEMIC.HIKMA - FOCUSED OUR US AND GLOBAL MANUFACTURING CAPABILITIES ON PRODUCING MEDICINES THAT ARE IN HIGHEST DEMAND DUE TO OUTBREAK OF COVID-19.  Full Article

Hikma Pharmaceutical Maintains 2020 Revenue Outlook
Thursday, 30 Apr 2020 

April 30 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - TRADING STATEMENT.HIKMA - PROACTIVELY MANAGING OUR INVENTORY AND STOCK LEVELS AND WORKING CLOSELY WITH OUR SUPPLIER NETWORKS.HIKMA - FOR FULL YEAR, WE CONTINUE TO EXPECT GENERICS REVENUE IN RANGE OF $700 MILLION TO $750 MILLION.HIKMA - OUR GUIDANCE ASSUMES THAT WE WILL LAUNCH GENERIC ADVAIR DISKUS(®) IN SECOND HALF OF YEAR.HIKMA - CONFIDENT IN OUTLOOK FOR BRANDED BUSINESS & CONTINUE TO EXPECT REVENUE GROWTH IN CONSTANT CURRENCY TO BE IN MID-SINGLE DIGITS FOR FY IN 2020.HIKMA - SUBJECT TO APPROVAL AT TODAY'S ANNUAL GENERAL MEETING, WE WILL BE PAYING A FINAL DIVIDEND OF 30 CENTS PER SHARE.HIKMA - IN US AND EUROPE, WE ARE SEEING AN INCREASE IN DEMAND ACROSS OUR PORTFOLIO, DRIVEN IN PART BY COVID-19 OUTBREAK.HIKMA - EXPECT OUR CORE OPERATING MARGIN FOR GENERICS BUSINESS TO BE BETWEEN 16% AND 18% OR, INCLUDING LAUNCH OF GENERIC ADVAIR DISKUS(®), AROUND 20%.  Full Article

Hikma Pharma Extends Voluntary Nationwide Recall Of Ketorolac Tromethamine Injections Due To Potential Small Particulate Presence
Thursday, 5 Mar 2020 

March 4 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICALS USA INC. EXTENDS VOLUNTARY NATIONWIDE RECALL OF KETOROLAC TROMETHAMINE INJECTION, USP 30MG/ML, 1ML FILL/2ML VIALS DUE TO POTENTIAL PRESENCE OF SMALL PARTICULATES.HIKMA - PRODUCT BEING RECALLED DUE TO PRESENCE OF SMALL VISIBLE PARTICULATE MATTERS OF GELATINOUS/OILY NATURE THAT APPEAR BLACK IN SOME RECALLED LOTS.HIKMA - LOTS BEING RECALLED WERE MANUFACTURED BETWEEN MARCH 22, 2018 AND FEBRUARY 21, 2019.HIKMA - INVESTIGATED CAUSE OF PROBLEM AND DECIDED TO SUSPEND MANUFACTURING OF PRODUCT.  Full Article

Hikma CEO Says Co Building Inventory Of Some Flu-Related Treatments - Interview
Thursday, 27 Feb 2020 

Feb 27 (Reuters) - :HIKMA CEO SAYS CO BUILDING INVENTORY OF SELECTIVE FLU-RELATED TREATMENTS IN CASE CORONAVIRUS OUTBREAK WORSENS AND SHORTAGES COME UP - INTERVIEW.  Full Article

Hikma Pharmaceutical Enters Into Agreement To Commercialise Ryaltris™
Thursday, 27 Feb 2020 

Feb 27 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ENTERS AGREEMENT TO COMMERCIALISE RYALTRIS™.CO AND GLENMARK SPECIALTY S.A., UNIT OF GLENMARK PHARMACEUTICALS, ANNOUNCE SIGNING OF US LICENSE AGREEMENT TO COMMERCIALISE RYALTRIS.UNDER TERMS, GLENMARK WILL BE RESPONSIBLE FOR CONTINUED DEVELOPMENT AND REGULATORY APPROVAL OF RYALTRIS™ BY US FOOD AND DRUG ADMINISTRATION.HIKMA WILL BE RESPONSIBLE FOR COMMERCIALISATION OF RYALTRIS™ IN US FOLLOWING APPROVAL.HIKMA WILL PROVIDE GLENMARK WITH AN UPFRONT PAYMENT, REGULATORY APPROVAL AND COMMERCIAL MILESTONE PAYMENTS AS WELL AS ROYALTIES.  Full Article

Photo

UK's Hikma making Gilead's COVID-19 drug remdesivir to increase supply

Britain's Hikma Pharmaceuticals said on Friday it has started manufacturing Gilead's antiviral drug remdesivir under contract in Portugal, as the U.S. company outsources to increase availability of the COVID-19 treatment.